Non-Small Cell Lung Cancer Coverage from Every Angle

Are Immune-Related Adverse Events With Nivolumab Linked to Efficacy in NSCLC?

By: Bruce Cleary
Posted: Tuesday, November 7, 2017

The presence of immune-related adverse events is associated with improved survival outcome in patients with advanced or recurrent non–small cell lung cancer (NSCLC) treated with nivolumab, according to a retrospective study by Koji Haratani, MD, of Kindai University Faculty of Medicine, Japan, and colleagues reported in JAMA Oncology. The authors concluded that, “Early recognition and proper management of immune-related adverse events are important to maximize the therapeutic benefit of immune-checkpoint inhibitors in patients with NSCLC.”

The authors performed a multiple-institution study of 134 patients with advanced or recurrent NSCLC who were treated with the programmed cell death protein 1 inhibitor nivolumab in a second-line or later setting. Immune-related adverse events were reported in approximately half of these patients.

The study’s 6-week landmark analysis suggested an association between immune-related adverse events and both progression-free and overall survival. In those with immune-related adverse events, progression-free and overall survival were 9.2 months and not reached, compared with 4.8 months and 11.1 months, respectively, in those without immune-related adverse events.

The authors noted additional studies with more patients and longer follow-up are needed to validate their findings.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.